Quantitative PET readouts of PDGFRβ expression may ultimately serve as both a diagnostic biomarker and a pharmacodynamic endpoint in clinical trials targeting myocardial fibrosis. The gene discussed is PDGFRB; the disease is Myocardial fibrosis.